How to use Technology Searches

Summary

BioXell is looking for urology, inflammation, gynecology, and gastrointestinal therapeutic candidates

Organization name

BioXell SpA

Profile

BioXell is an Italian biopharmaceutical company developing innovative drug candidates for unmet medical needs in urology, inflammation and other selected areas.

BioXell’s lead compound, Elocalcitol, is emerging as a potential new first-line monotherapy for lower urinary tract disorders, with a unique profile of action on the bladder and prostate and an outstanding safety record. BXL746, also derived from the Vitamin D3 class of compounds in which the Company has world-leading expertise, has generated highly positive preclinical data in the widespread and underserved indication post-surgical adhesions.

BioXell seeks to build a diversified and well balanced product portfolio through in-house research and development as well as in-licensing and/or product acquisition in its core business areas:

  • urology
  • gynecology
  • women's health
  • inflammation
  • gastrointestinal disorders
  • pain.

Additional information is provided online.    


URL

http://www.bioxell.com


Your Feedback

back

Search


Sector
Technology
Development Stage
Disease Category
Organ

latest entries